Please assess the completion status of the following clinical trial:

Trial Title: Study of Patients With Chronic Hepatitis C Infected With HCV LVL G1 and Effect of Peg-Intron Plus Rebetol Treatment (Study P04793)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Willingness to participate~* 18 years or older, either gender, any race~* Must have Hepatitic C Virus Low Viral Load \[LCV LVL\] (positive, but \<600,000 IU/mL on the assay used by the individual study site. Only Hepatitis C Virus-Ribonucleic acid/quantitative polymerase chain reaction \[HCV-RNA/qPCR\] assays with results in IU/ml are acceptable) AND been diagnosed with Genotype 1~* Subject considered suitable for treatment per local label~* Investigator considers suitable and subject consents to be treated~Exclusion Criteria:~* Does not show negative polymerase chain reaction \[PCR\] at week 4~* Pregnant women or those who plan to become pregnant or sexual partners of women who plan to become pregnant~* Subject does not qualify based on contra-indication, special warning, special population, and/or pregnancy \& lactation section of the Summary of Product Characteristics \[SmPC\]

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PegIntron plus Rebetol (Type: None): Those with chronic Hepatitis C infected with HCV LVL G1

Based on this trial design, predict the completion outcome and termination type (if applicable).